The third quarter saw a raft of first-in-class approvals, including the first RNA interference (RNAi) drug, the first nanobody, and a novel immunotoxin combining a CD22 Fv antibody fragment and an exotoxin. RNAi, antisense and small molecules achieved clinical… Fonte: VOLUME 36 NUMBER 12 DECEMBER 2018 NATURE BIOTECHNOLOGY Para acessar a publicação na íntegra clique aqui…
Biopharmaceutical benchmarks 2018
Antibodies continue to dominate biopharmaceutical approvals, but new nucleic acid modalities and cellular therapies are also slowly launching on the market. This article provides an update on three previous surveys of biopharmaceutical approvals1–3. Fonte: VOLUME 36 NUMBER 12 DECEMBER 2018 NATURE BIOTECHNOLOGY Para acessar a publicação na íntegra clique aqui …